Royal Bank Of Canada restated their outperform rating on shares of Valeant Pharmaceuticals Intl Inc (TSE:VRX) in a research report report published on Monday morning, reports. The firm currently has a C$46.00 price objective on the specialty pharmaceutical company’s stock.

Other equities research analysts have also recently issued reports about the company. TD Securities reissued a hold rating and set a C$38.00 price target on shares of Valeant Pharmaceuticals Intl in a report on Thursday, July 14th. Scotiabank decreased their price target on Valeant Pharmaceuticals Intl from C$35.00 to C$32.00 and set a sector perform rating on the stock in a report on Monday, July 25th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock currently has an average rating of Buy and a consensus target price of C$38.67.

Analyst Recommendations for Valeant Pharmaceuticals Intl (TSE:VRX)

Valeant Pharmaceuticals Intl (TSE:VRX) opened at 31.29 on Monday. The firm has a 50-day moving average price of $36.42 and a 200-day moving average price of $35.30. The company’s market capitalization is $10.87 billion. Valeant Pharmaceuticals Intl has a 52 week low of $24.32 and a 52 week high of $240.40.

About Valeant Pharmaceuticals Intl

Valeant Pharmaceuticals International, Inc is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries.

Stock Target Prices

Receive News & Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related companies with's FREE daily email newsletter.